LMR Partners’s Oric Pharmaceuticals ORIC Stock Holding History

LMR Partners’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$447K	Hold	35,267	–	–	﹤0.01%	1098
2025 Q4	$288K	Hold	35,267	–	–	﹤0.01%	1220
2025 Q3	$423K	Hold	35,267	–	–	﹤0.01%	1114
2025 Q2	$358K	Sell	35,267 -33	-0.1%	-$222	﹤0.01%	1020
2025 Q1	$197K	Buy	+35,300	New	+$309K	﹤0.01%	1064
2023 Q2	–	Sell	-23,780	Closed	-$136K	–	1051
2023 Q1	$136K	Buy	+23,780	New	+$124K	﹤0.01%	904
2022 Q4	–	Sell	-11,277	Closed	-$36K	–	1222
2022 Q3	$36K	Hold	11,277	–	–	﹤0.01%	1127
2022 Q2	$51K	Buy	+11,277	New	+$45K	﹤0.01%	1157

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

LMR Partners's ORIC Position: Q1 2026 in Review

LMR Partners held its Oric Pharmaceuticals (ORIC) position steady in Q1 2026 at 35,267 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

LMR Partners first reported a position in ORIC in Q2 2022 and has held it in 8 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

LMR Partners held 35,267 shares of Oric Pharmaceuticals worth $447K as of Q1 2026.
LMR Partners left its Oric Pharmaceuticals share count unchanged in Q1 2026.
Oric Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1098 holding.
LMR Partners first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.